Literature DB >> 35477810

Impact of Early Supportive Care Assessment on treatment decision in head and neck cancer before concomitant chemoradiotherapy.

François Cherifi1, Maud Villemin2,3, Frederique Bisiaux4, Alison Johnson3, Heidi Solem Laviec4, Audrey Rambeau3,4.   

Abstract

OBJECTIVE: To assess the impact of a global pretherapeutic comprehensive supportive care assessment performed in an outpatient supportive care clinic (OSCC) and early supportive care interventions on oncological treatment choice in patients with chemoradiation (CRT) indication for head and neck cancer (HNC).
METHODS: In this monocentric prospective observational study, we included all patients considered for CRT (exclusive or post-operative) for HNC from February 2019 to March 2020. The following frailty indicators were assessed: comorbidities (Charlson index), nutritional status, altered functional ability (ADL and IADL), social precarity (EPICES score), cognitive impairment (MoCA score), addictive habits and pain.
RESULTS: OSCC led to a change in treatment for 13.7% of patients, mainly de-escalations. Ninety-three percent of patients had at least one altered domain, including 50% with three or more altered domains. Cognitive function was the most frequently altered domain (66.7%). Altered functional ability was significantly associated with treatment de-escalation after OSCC. Treatment interruptions were significantly associated with treatment de-escalation and social precarity. De-escalation was also associated with a significantly poorer PFS (median of 23.2 mos. vs 8.8 mos., HR = 2.18 95%IC[1.02-4.63] p = 0.037)) and a non-significant trend towards worse OS (median 23.3mos. vs not reached (HR = 2.16 95%CI[0.88-5.31] p = 0.0836).
CONCLUSION: We strongly encourage the creation of OSCC for patients treated with chemoradiation for HNC. This practice, through an exhaustive assessment, favours therapeutic adaptation, personalized follow-up and optimization of supportive care.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chemoradiotherapy; Frailty comprehensive assessment; Head and Neck Cancer; Supportive care; outpatient clinic

Mesh:

Year:  2022        PMID: 35477810     DOI: 10.1007/s00520-022-07078-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  27 in total

1.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Authors:  Phuc Felix Nguyen-Tan; Qiang Zhang; K Kian Ang; Randal S Weber; David I Rosenthal; Denis Soulieres; Harold Kim; Craig Silverman; Adam Raben; Thomas J Galloway; André Fortin; Elizabeth Gore; William H Westra; Christine H Chung; Richard C Jordan; Maura L Gillison; Marcie List; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

Review 2.  Head and neck cancer--Part 1: Epidemiology, presentation, and prevention.

Authors:  H Mehanna; V Paleri; C M L West; C Nutting
Journal:  BMJ       Date:  2010-09-20

3.  Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  V Grégoire; J-L Lefebvre; L Licitra; E Felip
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

4.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

Authors:  Lester J Peters; Brian O'Sullivan; Jordi Giralt; Thomas J Fitzgerald; Andy Trotti; Jacques Bernier; Jean Bourhis; Kally Yuen; Richard Fisher; Danny Rischin
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

5.  Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment.

Authors:  Giorgio Capuano; Pier Carlo Gentile; Federico Bianciardi; Michela Tosti; Anna Palladino; Mario Di Palma
Journal:  Support Care Cancer       Date:  2009-06-29       Impact factor: 3.603

Review 6.  Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials.

Authors:  Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter
Journal:  J Natl Cancer Inst       Date:  2013-03-06       Impact factor: 13.506

7.  Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).

Authors:  Lorraine Walsh; Charles Gillham; Mary Dunne; Ian Fraser; Donal Hollywood; John Armstrong; Pierre Thirion
Journal:  Radiother Oncol       Date:  2010-12-13       Impact factor: 6.280

8.  Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.

Authors:  Audrey Rambeau; Radj Gervais; Dominique De Raucourt; Emmanuel Babin; Audrey Emmanuelle Dugué; Carmen Florescu; David Blanchard; Bernard Gery
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-05       Impact factor: 2.503

Review 9.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

10.  Effect of smoking, alcohol, and depression on the quality of life of head and neck cancer patients.

Authors:  Sonia A Duffy; Jeffrey E Terrell; Marcia Valenstein; David L Ronis; Laurel A Copeland; Mary Connors
Journal:  Gen Hosp Psychiatry       Date:  2002 May-Jun       Impact factor: 3.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.